Skip to main content

Table 3 The relation of  EGFR  gene copy number status with progression-free survival and overall survival

From: EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

Study

Median PFS (mo)

HR

 P 

Median OS (mo)

HR

 P 

GCN + vs GCN-

GCN + vs GCN-

Bengala 200925

--

--

NS

--

--

NS

Campanella 201026

--

0.54

0.03

--

--

--

Cappuzzo 200823

6.6 vs 3.5*

--

0.02

11.3 vs 8.5*

--

0.8

Goncalves 200829

4.1 vs 3.3

--

--

--

--

--

Italiano 200815

--

--

0.70

--

--

0.82

Khambata-Ford 200730

4.8 vs 2.0

--

--

--

--

--

Laurent-Puig 200916

7.9 vs 6.5

--

0.280

19.7 vs 13.9

--

0.180

Mancuso 200832

6.2 vs 3.2

--

0.003

--

--

--

Perrone 200924

6 vs 5

--

--

--

--

--

Personeni 200833

5.5 vs 4

--

0.25

10 vs 8.3

--

0.037

Razis 200834

8.7 vs 6.4-6.9*

0.82

NS

--

--

--

Sartore-Bianchi 200717

--

--

0.039

--

--

0.015

Sastre 200935

4.9 vs 2.6

--

0.03

11.1

--

--

Scartozzi 200936

7.7 vs 2.9

--

0.04

16 vs 9.5

--

0.2

Tol 201037

9.5 vs 10.4

--

0.19

21.9 vs 22.0

--

0.65

  1. PFS, progression-free survival; mo, month; GCN+, increased gene copy number; GCN-, non-increased gene copy number; HR, hazard ratio; OS, overall survival; --, not available; NS, not significant (without detailed numerical values).
  2. * The original studies did not specify whether the number was “mean” or “median”.